Talis Biomedical Corporation (TLIS) |
|
5.7301 0.05 (0.88%)
|
09-28 15:17 |
|
Open: |
5.98 |
Pre. Close: |
5.68 |
|
High:
|
5.98 |
Low:
|
5.72 |
|
Volume:
|
1,811 |
Market Cap:
|
10(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:53:45 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 7.5 One year: 8.24 |
| Support: |
Support1: 5.4 Support2: 4.49 |
| Resistance: |
Resistance1: 6.42 Resistance2: 7.05 |
| Pivot: |
5.91 |
| Moving Average: |
MA(5): 5.7 MA(20): 5.96
MA(100): 7 MA(250): 7.87 |
| MACD: |
MACD(12,26): -0.3  Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 32.4 %D(3): 24.6 |
| RSI: |
RSI(14): 42.1 |
| 52-week: |
High: 12.75 Low: 5.4 |
| Average Vol(K): |
3-Month: 14 (K) 10-Days: 8 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TLIS ] has closed above bottom band by 32.3%. Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.99 - 6.02 |
6.02 - 6.05 |
|
Low:
|
5.64 - 5.68 |
5.68 - 5.71 |
|
Close:
|
5.68 - 5.74 |
5.74 - 5.79 |
|
Company Description |
|
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. |
Headline News |
Tue, 05 Sep 2023
Stocks That Hit 52-Week Lows On Tuesday - Frontier Group Holdings (NASDAQ:ULCC), United Natural Foods (NY - Benzinga
Wed, 02 Aug 2023
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President ... - BioSpace
Fri, 28 Jul 2023
In Brief This Week: Yourgene Health, Illumina, Delfi Dx, Enzo ... - GenomeWeb
Thu, 27 Jul 2023
New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu - Yahoo Finance
Mon, 24 Jul 2023
Talis Biomedical regains compliance with Nasdaq's minimum bid ... - Seeking Alpha
Wed, 05 Jul 2023
Talis Biomedical Announces 1-for-15 Reverse Stock Split - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
0 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
979640 (%) |
|
% Held by Institutions
|
8.4 (%) |
|
Shares Short
|
23 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.886e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-3 |
|
Return on Assets (ttm)
|
39.7 |
|
Return on Equity (ttm)
|
-31.5 |
|
Qtrly Rev. Growth
|
2.85e+006 |
|
Gross Profit (p.s.)
|
1.39 |
|
Sales Per Share
|
-54.64 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-49.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-65 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.11 |
|
Price to Cash Flow
|
0.12 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
14000 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
